CIBC Asset Management Inc Grows Stock Holdings in Boston Scientific Corporation $BSX

CIBC Asset Management Inc grew its holdings in Boston Scientific Corporation (NYSE:BSX) by 65.1% during the 4th quarter, Holdings Channel reports. The fund owned 365,967 shares of the medical equipment provider’s stock after purchasing an additional 144,369 shares during the period. CIBC Asset Management Inc’s holdings in Boston Scientific were worth $34,895,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in BSX. Vanguard Group Inc. boosted its holdings in Boston Scientific by 0.8% during the third quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock worth $13,497,294,000 after buying an additional 1,115,337 shares in the last quarter. Rathbones Group PLC boosted its holdings in Boston Scientific by 20.9% during the fourth quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock worth $263,133,000 after buying an additional 477,680 shares in the last quarter. Tounjian Advisory Partners LLC purchased a new stake in Boston Scientific during the fourth quarter worth $1,477,000. Kepler Cheuvreux Suisse SA purchased a new stake in Boston Scientific during the third quarter worth $26,955,000. Finally, Waycross Partners LLC purchased a new stake in Boston Scientific during the fourth quarter worth $2,384,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on BSX shares. UBS Group lowered their price target on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a report on Tuesday, March 17th. Raymond James Financial reissued an “outperform” rating and set a $88.00 price target (down from $97.00) on shares of Boston Scientific in a report on Monday, March 30th. BTIG Research lowered their price target on shares of Boston Scientific from $80.00 to $65.00 and set a “buy” rating on the stock in a report on Tuesday. Wells Fargo & Company reissued an “equal weight” rating and set a $55.00 price target (down from $75.00) on shares of Boston Scientific in a report on Thursday, May 28th. Finally, Royal Bank Of Canada reissued an “outperform” rating on shares of Boston Scientific in a report on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $86.79.

Boston Scientific Stock Performance

BSX opened at $47.79 on Thursday. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The company has a market cap of $71.03 billion, a price-to-earnings ratio of 19.99, a PEG ratio of 0.89 and a beta of 0.56. Boston Scientific Corporation has a 52-week low of $47.17 and a 52-week high of $109.50. The firm’s fifty day simple moving average is $58.92 and its two-hundred day simple moving average is $77.28.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company’s revenue was up 11.6% compared to the same quarter last year. During the same period last year, the firm posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts anticipate that Boston Scientific Corporation will post 3.37 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has approved a share buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling at Boston Scientific

In related news, Director David C. Habiger acquired 2,250 shares of the firm’s stock in a transaction on Wednesday, May 20th. The shares were acquired at an average cost of $55.92 per share, with a total value of $125,820.00. Following the completion of the acquisition, the director directly owned 13,878 shares in the company, valued at approximately $776,057.76. This trade represents a 19.35% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Edward J. Ludwig bought 3,580 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average price of $56.68 per share, with a total value of $202,914.40. Following the completion of the transaction, the director directly owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 9,800 shares of company stock valued at $554,012 over the last ninety days. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.